Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-6222 in Adult Participants With Obesity
NCT07624071Phase 1Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing ALN-6222 with Placebo (2 arms). Primary endpoint: Frequency of Adverse Events at 12 months. Started Jun 2026; status: recruiting.
02
Drugs
ALN-6222
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07624071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624071.